Therefore, developing targeted therapeutic drugs against key proteins such as YTHDC1 and METTL3, based on the regulatory mechanisms of m6A modification, holds promise for enhancing the anti-tumor functions of B cells. This evidence concerns the gene METTL3 and neoplasm.